Oxford COVID vaccine data could go before regulators this year: director By Reuters

2/2
© Reuters. FILE PHOTO: Britain’s William, Duke of Cambridge, visits the Oxford Vaccine Group’s facility at the Churchill Hospital, in Oxford

2/2

LONDON (Reuters) – An experimental COVID-19 vaccine being developed by the University of Oxford and AstraZeneca (NYSE:) could be put before regulators this year if scientists are able to gather enough data, the director of the Oxford Vaccine Group said on Tuesday.

“It is just possible that if the cases accrue rapidly in the clinical trials, that we could have that data before regulators this year, and then there would be a process that they go through in order to make a full assessment of the data,” Andrew Pollard told BBC Radio.

The Oxford vaccine showed early promise in the first human trial when it produced an immune response, underlining its position as one of the leading candidates in the race to produce a vaccine against a disease that has crippled the global economy.

The trial hit the headlines earlier this week when the Financial Times reported that the Trump administration was considering fast-tracking the vaccine for use in the United States ahead of the Nov. 3 elections.

One option being explored would involve the U.S. Food and Drug Administration (FDA) awarding “emergency use authorization” in October to the potential vaccine, the FT said.

“The process of going through emergency use authorization in an emergency is well established, but it still involves having carefully conducted data… and evidence that it actually works,” Pollard said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*